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Introduction
The PI5P4Ks
The phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks) are a family consisting of three isoforms in mammals (α, β, and γ), whose most likely function is currently believed to be the regulation of the levels of their substrate, PI5P (see refs (Bulley et al., 2015 , Clarke and Irvine, 2012 , Clarke et al., 2010 ) for reviews). This view stems from the comparatively low levels of its substrate, PI5P, compared to the amounts of PI4P, the substrate of the PI4P5Ks, which synthesise the bulk of the cell's PI(4,5)P 2 (see for example, (Clarke et al., 2001 , Roberts et al., 2005 ). Some recent work from our laboratory (S. Bulley et al, unpublished) has pointed to the possibility that synthesis of a local, minor pool of PI(4,5)P 2 might be a physiologically significant function of PI5P4Kα.
The α and β isoforms have been assigned some physiological and pathological functions, which include roles in gene regulation (Gelato et al., 2014 , Shah et al., 2013 , stress responses (Keune et al., 2013) , insulin signalling (Lamia et al., 2004) and cancer , Fitzgerald and McCubrey, 2014 , Jude et al., 2014 -see (Fiume et al., 2015) for review. Also, PI5P generated during bacterial infection has been shown to have a function in regulating that process, primarily by altering cytoskeletal function (Niebuhr et al., 2002 , Ramel et al., 2011 .
PI5P
Physiological roles for PI5P associated with the cytoskeleton have also been reported (reviewed in detail in (Bulley et al., 2015) ). For example, overexpression of the PI5P-generating enzyme PIKfyve or microinjection of PI5P mimics insulin's effects on Factin stress fibres (Sbrissa et al., 2004) , and studies from Wesche's lab (Haugsten et al., 2013 , Oppelt et al., 2014 , Oppelt et al., 2013 imply that PI5P is a signalling intermediate in FGF1-stimulated cell migration. FGF1 induces PI5P production and promotes cell migration in BJ fibroblasts (Oppelt et al., 2013) , effects that are attenuated by knockdown of the PI5P-generating enzymes PIKfyve and MTMR3.
Moreover, overexpressing PI5P4Kα in order to deplete cellular PI5P decreases cell M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT migration velocity (Haugsten et al., 2013) , while Rac has been shown to be an effector of these effects, which may contribute to cell migration and metastasis (Oppelt et al., 2014) . Recently, PI5P has been implicated in autophagy (Vicinanza et al., 2015) .
Nuclear functions of PI5P have also clearly indicated (Bulley et al., 2015) , with two important effectors being ING-2 (Bua et al., 2013 , Gozani et al., 2003 and UHRF1 (Gelato et al., 2014) . Given that both PI5P4Ks α and β are found in the nucleus (Bultsma et al., 2010 , Ciruela et al., 2000 , Wang et al., 2010 , it remains unclear as the relative contributions of these PI5P4Ks to these events (though the contribution of PI5P4Kβ to stress responses in the nucleus has been clearly shown (Jones et al., 2006) ).
PI5P4Kγ
Background This is currently the least understood of the PI5P4K isoforms. It is apparently ubiquitously expressed, but at very different levels between tissues, being particularly high in epithelial cells of the thick ascending limb of the kidney and collecting duct cells (Clarke et al., 2008) and in specific neurons in brain (Clarke et al., 2009) . It apparently has a vesicular localization (Clarke et al., 2008 , Clarke et al., 2009 ), which we have recently confirmed by GFP-tagging the enzyme using CRISPR-Cas-9 technology in mpkCCD cells (M-L.G. & R.F.I. unpublished). PI5P4Kγ has been reported to have a specific (not shown by PI5P4Ks α or β) functional connection with Rho (Yih et al., 2012) . Also some compelling evidence has recently linked PI5P4Kγ to mTORC1 (Mackey et al., 2014) . mTORC1 phosphorylates PI5P4Kγ, causing it to change its cellular localisation, and PI5P4Kγ exerts a regulatory influence on mTORC1 (which is in turn changed if it is phosphorylated), shown most clearly in Tsc2 knocked-down cells (Mackey et al., 2014) .
One of the most puzzling features of PI5P4Kγ is that it has a much lower enzymatic activity in vitro than the other PI5P4K isoforms, which we have shown lies primarily M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
at the ATP binding site, as if this is incrementally mutated to resemble the PI5P4Kα ATP site, the enzyme shows increasing activity (Clarke and Irvine, 2013) . PI5P4Kγ can heterodimerise in vitro with PI5P4Kα (Clarke and Irvine, 2013) , and as extensive heterodimerisation between PI5P4Ks α and β has been shown to occur in vivo (Bultsma et al., 2010 , Wang et al., 2010 , a potential function for PI5P4Kγ as a 'targeting' protein for the other two (much more active) though our more recent investigations (below) have made this hypothesis appear increasingly unlikely.
Inhibition
Our own recent investigations of PI5P4Kγ have used RNAi knockdown and a very specific inhibitor, NIH-12848, which interacts with the PI5P-binding site of PI5P4Kγ . The removal of PI5P4Kγ by RNAi (but not removal of PI5P4Ks α or β) closely mimics the effects of the inhibitor in preventing the formation of the polarised phenotype that mpkCCD cells adopt, including localisation of the Na + /K + ATPase and formation of domes on the culture dish. This phenotype is superfically consistent with the polarised distribution of PI5P4Kγ in epithelial cells in the kidney in vivo (Clarke et al., 2008) .
Inhibiting PI5P4Ks
Specific inhibitors of enzymes can be useful tools in studying their function, and the fortuitous discovery of such a specific inhibitor for PI5P4Kγ will be of great value in the future. The recent characterization of inhibitors for PI5P4Kα (Davis et al., 2013) and PI5P4Kβ (Voss et al., 2014) have raised that hope for those isoforms too, but the isoform specificity of neither inhibitor has yet been established. Moreover, a challenge facing ATP-binding site inhibitors (the majority), is for them to have both sufficient specificity (because all kinase ATP binding sites show some structural similarity) and potency (cellular concentrations of ATP are in the millimolar range, so nanomolar affinity of an inhibitor is often required for micromolar efficacy in a cell).
Designing PI5P4Kα and PI5P4Kβ inhibitors to bind instead to the PI5P binding site, as NIH-12848 does to PI5P4Kγ, might move us a significant step closer to pharmaceutical application. The PI5P4Kγ mutated so that its ATP site is similar to M A N U S C R I P T
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PI5P4Kα (PI5P4Kγ + (Clarke and Irvine, 2013) ) might be a valuable tool in this respect, as, for example, any inhibitor emerging from a PI5P4Kα screen could be immediately tested against PI5P4Ks β and γ (for isoform specificity) and also PI5P4Ks β+ and γ+ (Clarke and Irvine, 2013) . Any compound that inhibits these latter two with an efficacy similar to that on PI5P4Kα could be eliminated as likely to be interacting with the ATP-binding site, whereas any showing a similar isoform specificity to the wild type PI5P4Ks β and γ is probably interacting with the PI5P site or an allosteric site.
We have carried out a simple proof of principle experiment to address this idea using the PI5P4Kα inhibitor I-OMe Tyrphostin AG-538 (Davis et al., 2013) , which targets the ATP site. We looked at the inhibition of the three PI5P4K isoforms, and also two mutant PI5P4Kγs: PI5P4Kγ+, which has its ATP site mutated to be similar to that of PI5P4Kα (Clarke and Irvine, 2013) , and PI5P4Kγ N165I, which is mutated in the PI5P-binding site to make it resistant to NIH-12848 . The data show that at a concentration of 20µM, AG-538 induces an almost complete inhibition of PI5P4Kα, inhibits PI5P4Ks β and γ by 90% and 85% respectively, indicating that although it favours PI5P4Kα, it is not very isoform specific (compare NIH-12848 against PI5P4Kγ ). However, the most interesting observation from these data is that PI5P4Kγ+ is, as we would expect, as sensitive to AG-538 inhibition as is PI5P4Kα, while PI5P4Kγ N165I is exactly the same as WT PI5P4Kγ.
On this basis, AG-538 would be eliminated from the screen as being likely binding to the ATP site of PI5P4Kα, which it does.
Thus these data support a simple proof of principle that inhibitors for PI5P4Kα that interact through sites different from the ATP-binding site can be discovered using PI5P4Kγ+ (and PI5P4Kβ+, generated on the same logic as PI5P4Kγ+ (Clarke and Irvine, 2013) ) as screening tools. The remarkable specificity of NIH-12848 for PI5P4Kγ that we have demonstrated is certainly something that would be valuable to replicate for the other PI5P4K isoforms. Enzymes were prepared and assayed as in (Clarke and Irvine, 2013) and . Data (mean of triplicates) show the residual activity of each enzyme (as %) compared to the absence of inhibitor.
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